Robust immune response to the BNT162b mRNA vaccine in an elderly population vaccinated 15 months after recovery from COVID-19

Knowledge about the impact of prior SARS-CoV-2 infection of the elderly on mRNA vaccination response is needed to appropriately address the need for booster vaccination in this vulnerable population. To address this, we investigated antibody and genomic immune responses in 16 elderly (avg. 81 yrs.) individuals that had received a single booster dose of BNT162b vaccine 15 months after recovering from COVID-19. Spike-specific IgG antibody levels increased in each of the study participants from an average of 710 U/ml prior to the vaccination to more than 40,000 U/ml within ten weeks after the vaccination. In contrast, anti-spike-specific IgG antibody levels averaged 2,190 U/ml in 14 healthy SARS-CoV-2-naïve individuals (avg. 58 yrs.) ten weeks after the second dose of BNT162b. RNA-seq conducted on PBMCs demonstrated the activation of interferon-activated genetic programs in both cohorts within one day. Unlike their transient induction in the younger naïve population, persistent activity and the initiation of additional cell cycle regulated programs were obtained in the older COVID-19 recovered population. Here we show that the elderly, a high-risk population, can mount a strong antibody and a persistent molecular immune response upon receiving a single dose of mRNA vaccine 15 months after recovery from COVID-19.


Introduction
BNT162b mRNA COVID-19 vaccines have been shown to elicit strong antibody responses 1,2 and be highly efficacious in real world settings 3 . While current research focuses on the long-term effectiveness and waning immunity 4 in real world settings 5 , only few studies on vaccine efficacy in the elderly population have been reported 6,7 .
Immunosenescence, defined as age-related decline of the immune system, has been associated with poor vaccine responses in older adults 8 and previous studies have reported a negative relationship between age and mRNA vaccine-induced antibody titers 9,10 . However, recent data suggest that two doses of BNT162b elicit high IgG levels and serum neutralization in a SARS-CoV-2 antigen-naïve elderly population 7 . While optimal increases in antibody levels in SARS-CoV-2 antigen-naïve individuals requires two mRNA vaccine doses, individuals with prior SARS-CoV-2 infection have naturally acquired immunity and a single dose of vaccine is likely sufficient to boost antibody for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.08.21263284 doi: medRxiv preprint responses 10-12 . Yet, these studies have been conducted on younger cohorts, mainly health care workers, and the immune response of elderly COVID-19 recovered individuals (> 70 years) to a single dose of mRNA vaccines remains to be understood.
Studies on SARS-CoV-2 antigen-naïve and COVID-19 recovered subjects inoculated with mRNA vaccines have largely focused on measuring binding and/or neutralizing antibodies as primary end points. However, there is a definitive need to also understand the molecular immune responses after vaccination, both in COVID-19 recovered and SARS-CoV-2 antigen-naïve individuals.
Here we have addressed these knowledge gaps and assessed the immune response in an elderly population in a convent that experienced a SARS-CoV-2 outbreak in the spring of 2020. Sixteen nuns (avg. 82 yr.) that had recovered from COVID-19, received the primary booster vaccination 15 months after the initial infection.
We assessed their antibody response and genomic responses through RNA-seq of peripheral blood mononuclear cells (PBMCs). As control, we investigated 14 SARS-CoV-2 naïve individuals (avg. 58 yr.) receiving two doses of BNT162b.
This real-world study provided critical information on the shared and unique molecular vaccine response and antibody production in two distinct groups, elderly individuals that were vaccinated 15 months after recovering from COVID-19 and naïve individuals receiving the two-dose regimen.

Results
Here we investigated the immune response to the BNT162b vaccine of an elderly population recovered from COVID- 19 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Symptoms and systemic cytokine levels after BNT162b vaccination
Four out of the 16 elderly COVID-19 recovered individuals (Fig. 1d) reported postvaccine symptoms, fatigue and joint pain, after the primary (booster) dose (Supplementary Table 1). No symptoms were reported by the healthy SARS-CoV-2naïve individuals after their second (booster) vaccination (Supplementary Table 1).
Next, we measured serum levels of a panel of cytokines in the COVID-19 recovered individuals prior to and after the primary booster vaccination, and prior to and after the second (booster) vaccination in the SARS-CoV-2 antigen-naïve group ( Fig. 2; Supplementary Table 2). Out of the 10 cytokines measured, an increase of circulating IFNg and CXCL10 was observed in both groups within one day following vaccination ( Fig. 2a-b). IFNg levels in both groups returned to baseline levels at day 7 ( Fig. 2c-d). By day 7, CXCL10 levels had returned to baseline in the naïve group but remained elevated in the COVID-19 recovered group (Fig. 2c-d) suggesting an extended immune response. Levels of the other cytokines tested (IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-16, IL-1b, TNF-a and VEGF) were unchanged in the COVID-19 recovered group ( Supplementary Fig. 1). In contrast, in the naïve group, IL-16 levels declined post vaccination and IL-8 levels increased at day 7 post vaccination ( Supplementary Fig. 1b).

Antibody responses to BNT162b vaccination
We first measured circulating antibody responses in serum samples by enzyme-linked immunosorbent assay (ELISA). All elderly COVID-19 recovered individuals had levels of anti-spike IgG ranging from 34 U/ml to >2,500 U/ml (average 706 U/ml) at 10 months after developing COVID-19 ( This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This demonstrates an approximately 20-fold elevated response in the elderly, previously infected cohort.

Transcriptome response of COVID-19 recovered and SARS-CoV-2 antigen-naïve individuals
The exceptional response of the COVID-19 recovered individuals to the booster vaccination promoted us to investigate the molecular innate immune response. We  Table 1).
PCA plot analysis indicated that the greatest transcriptome differences in the COVID-19 recovered individuals were found at day 7 post vaccination ( Fig. 3a). A total of 161 genes were induced at least two-fold within one day after the booster vaccination  Table 5) and 652 genes were activated between day 1 and day 7 (Supplementary Table   6). Gene-set enrichment analysis (GSEA) demonstrated that the genes activated within one day after the vaccination were enriched in immune-response, interferon and JAK-STAT pathways ( Supplementary Fig. 2). The SARS-CoV-2 naïve group exhibited a distinctly different transcriptome response ( Fig. 3c and Table 9). As expected, the genes activated at day 1 were part of interferon and cytokine pathways ( Supplementary Fig. 2d). We also investigated the immune transcriptomes prior to and after the primary vaccination of the SARS-CoV-2 antigen-naïve group and for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Differential transcriptome activation between COVID-19 recovered and SARS-CoV-2 naïve individuals
To further understand the stark differences to the booster vaccination between the two groups, we dug deeper and analyzed the longitudinal expression of the genes activated recovered population (Fig. 4d).
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Shared transcriptomes induced by different vaccines
Transcriptome (RNA-seq) studies have been reported for the hepatitis B vaccine 13 , influenza vaccines 14,15 and the BNT162b vaccine in a younger cohort (avg. 39 yrs.) 16 .
To understand transcriptome responses to different vaccines, we have compared genes reported to be activated in the published studies within 1-2 days post vaccination ( Supplementary Fig. 6). The immediate (day0) response to the BNT162b booster in our Naïve cohort was similar to that induced by the inactivated influenza vaccine and mRNA BNT162b2 vaccine. In contrast only five genes identified in the Hepatitis B vaccine study ( Supplementary Fig. 6). However, since the sequencing depth in these studies is significantly lower (~38 million reads per sample 16 as compared to 240 million in our study) a definitive direct comparison is challenging.

Discussion
In this real-world study we provide evidence that a single dose of the mRNA vaccine BNT162b elicits a strong immune response in an elderly population vaccinated 15 months after recovering from COVID-19. Aging is associated with a decline of the immune system, commonly referred to as immunosenescence, and increased chronic low-grade systemic inflammation, also referred to as inflammaging 17 , both coupled with a poor vaccine response 8 . However, our data demonstrate that the immune response to BNT162b in an elderly population (avg. 81 yrs.) previously infected with SARS-CoV-2 exceeds that of a younger SARS-CoV-2 naïve cohort (avg. 59 yrs.) receiving the twodose regimen.
The optimal window for providing the booster vaccine to individuals recovered from a previous SARS-CoV-2 infection has not been defined and might be agedependent. Recent studies have investigated the immune response in younger populations recovered from COVID-19 10,11,18-20 . In general, the immune responses, including spike-specific IgG antibody levels, in individuals younger than 50 years having received booster doses within one to six months after the original SARS-CoV-2 infection were similar to those seen after two doses of vaccine in individuals of similar age without prior infection 10, 11,18,21 . A large scale clinical study provided evidence that natural immune protection that develops after a SARS-CoV-2 infection followed by a single for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.08.21263284 doi: medRxiv preprint Results from this real-world study are encouraging for vaccine efficacy in the elderly previously infected with SARS-CoV-2. Antibody levels in this group greatly exceeded those in a younger cohort receiving the two-dose regimen. While the optimal window between previous infection and booster shot is not known, our study demonstrates that a 15-months gap did not negatively interfere with the immune response but resulted in a robust production of antibodies. This has practical implications for health care professionals making decisions on the need to booster vaccinations.

Limitations of this study
This elderly cohort previously infected with SARS-CoV-2 was from a narrowly defined geographically area and included only one gender (females). The infection occurred in the spring of 2020 and the viral strain had not been sequenced. The SARS-CoV-2 antigen-naïve population was from a narrowly defined geographically area. The study was confined to the BNT162b mRNA vaccine.

Study population, study design and recruitment.
Sixteen COVID-19 recovered volunteers who were infected with SARS-CoV-2 and This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.08.21263284 doi: medRxiv preprint guidelines and regulations. All research has been have been performed in accordance with the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-ofhelsinki-ethical-principles-for-medical-research-involving-human-subjects/). In addition, we followed the 'Sex and Gender Equity in Research -SAGER -guidelines' and included sex and gender considerations where relevant.

Quantification of immunoproteins.
Serum samples from all participants were collected from their blood. After thawing, serum samples were centrifuged for 3 minutes at 2000 g to remove particulates prior to sample preparation and analysis. The electrochemiluminescence V-PLEX assay (Meso Scale Discovery, MD) was used to measure proinflammatory proteins (IFN-g, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10 and TNF-a), cytokines (IL-15, IL16 and VEGF) and chemokine (CXCL10). Serum samples were diluted 2-fold and measured in duplicate. The cytokines concentration was determined with the electrochemiluminescent labels whilst the plate is inserted into the MSD instrument (MESO QUICKPLEX SQ 120). All samples were assayed in duplicate. High and low controls were used to assess variance between plates. The inter-assay coefficient of variations was <10%. The results were analyzed using MSD DISCOVERY WORKBENCH analysis software.

Anti-S binding ELISA
Anti-SARS-CoV-2 S-Protein antibodies were measured using the Roche Elecsys Anti-SARS-CoV-2 S immunoassay on a Cobas e411 analyzer (Roche Diagnostics, Basel, Switzerland) as described somewhere else 18 . In short, serum samples were incubated with biotinylated and adenylated recombinant SARS-CoV-2 RBD antigen. In presence of corresponding anti-SARS-CoV-2 antigens immune complexes were formed, which were bound to the solid phase after addition of streptavidin-coated microparticles.
Microparticle-bound antibodies were detected by electrochemiluminescence in the Cobas e411 analyzer. Results <0.8 U/mL were diagnosed as non-reactive, while results >0.8 U/mL were diagnosed as reactive.

Extraction of the buffy coat and purification of RNA
for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.08.21263284 doi: medRxiv preprint Whole blood was collected, and total RNA was extracted from the buffy coat and purified using the Maxwell RSC simply RNA Blood Kit (Promega) according to the manufacturer's instructions. The concentration and quality of RNA were assessed by an Agilent Bioanalyzer 2100 (Agilent Technologies, CA). mRNA sequencing (mRNA-seq) and data analysis.
The Poly-A containing mRNA was purified by poly-T oligo hybridization from 1 µg of total RNA and cDNA was synthesized using SuperScript III (Invitrogen, MA). Libraries for sequencing were prepared according to the manufacturer's instructions with TruSeq The raw data were subjected to QC analyses using the FastQC tool (version 0.11.9) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). mRNA-seq read quality control was done using Trimmomatic 19 (version 0.36) and STAR RNA-seq 20 (version STAR 2.5.4a) using 150 bp paired-end mode was used to align the reads (hg19).
HTSeq 21 (version 0.9.1) was to retrieve the raw counts and subsequently, Bioconductor package DESeq2 22 in R (https://www.R-project.org/) was used to normalize the counts across samples and perform differential expression gene analysis. Additionally, the RUVSeq 23 package was applied to remove confounding factors. The data were prefiltered keeping only genes with at least ten reads in total. The visualization was done using dplyr (https://CRAN.R-project.org/package=dplyr) and ggplot2 24 . The genes with log2 fold change >1 or <-1 and adjusted p-value (pAdj) <0.05 corrected for multiple testing using the Benjamini-Hochberg method were considered significant and then conducted gene enrichment analysis (GSEA, https://www.gsea-msigdb.org/gsea/msigdb).

Statistical analysis
Differential expression gene (DEG) identification used Bioconductor package DESeq2 in R. P-values were calculated using a paired, two-side Wilcoxon test and adjusted p-value (pAdj) corrected using the Benjamini-Hochberg method. Genes with log2 fold change >1 or <-1, pAdj <0.05 and without 0 value from all sample were considered significant. For for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Ethics approval
This study was approved (EK Nr:

Data availability
The RNA-seq data from this study will be uploaded in GEO before publishing the manuscript.

Acknowledgments
Our gratitude goes to the participants who contributed to this study to advance our This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.08.21263284 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted September 12, 2021. ; https://doi.org/10.1101/2021.09.08.21263284 doi: medRxiv preprint This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.